[
  {
    "ts": null,
    "headline": "Enanta Files Patent Lawsuit Against Pfizer (PFE) Over COVID-19 Drug Paxlovid",
    "summary": "Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, targeting the company's operations across the EU. Over the last quarter, Pfizer's stock saw a 10% increase, amidst a backdrop of mixed market trends, including a 1.5% decline in major indices. Significant events such as the resolution of mRNA vaccine-related litigation, strong Q2 earnings, and strategic product developments likely contributed positively to this growth. While...",
    "url": "https://finnhub.io/api/news?id=553daaef00be0bcf4df65fc8ffe0ab4cd106e538004997a9f4aa76d090824d89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755798110,
      "headline": "Enanta Files Patent Lawsuit Against Pfizer (PFE) Over COVID-19 Drug Paxlovid",
      "id": 136468841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, targeting the company's operations across the EU. Over the last quarter, Pfizer's stock saw a 10% increase, amidst a backdrop of mixed market trends, including a 1.5% decline in major indices. Significant events such as the resolution of mRNA vaccine-related litigation, strong Q2 earnings, and strategic product developments likely contributed positively to this growth. While...",
      "url": "https://finnhub.io/api/news?id=553daaef00be0bcf4df65fc8ffe0ab4cd106e538004997a9f4aa76d090824d89"
    }
  },
  {
    "ts": null,
    "headline": "Latest Fed cut signals, pharma relief rally, Apple TV+ price hike",
    "summary": "Yahoo Finance's John Hyland outlines three of the top stories on Wall Street as part of the Market Minute. Federal Reserve Bank of Cleveland President and CEO Beth Hammack tells Yahoo Finance at the Jackson Hole Economic Policy Symposium she wouldn't vote to cut interest rates if the central bank were to hold its policy meeting tomorrow. Pharmaceutical stocks like Teva Pharmaceutical (TEVA), Pfizer (PFE), and Eli Lilly (LLY), pop after the newly released details about the US-EU trade deal were better-than-feared for the industry. Apple (AAPL) lifts the price of its Apple TV+ subscription by 30% to $12.99 monthly. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=c63bf466a0cc03c9076b93c0386cd28383476ecfc874d2d33ab9e8f8059db064",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755796486,
      "headline": "Latest Fed cut signals, pharma relief rally, Apple TV+ price hike",
      "id": 136471389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Yahoo Finance's John Hyland outlines three of the top stories on Wall Street as part of the Market Minute. Federal Reserve Bank of Cleveland President and CEO Beth Hammack tells Yahoo Finance at the Jackson Hole Economic Policy Symposium she wouldn't vote to cut interest rates if the central bank were to hold its policy meeting tomorrow. Pharmaceutical stocks like Teva Pharmaceutical (TEVA), Pfizer (PFE), and Eli Lilly (LLY), pop after the newly released details about the US-EU trade deal were better-than-feared for the industry. Apple (AAPL) lifts the price of its Apple TV+ subscription by 30% to $12.99 monthly. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=c63bf466a0cc03c9076b93c0386cd28383476ecfc874d2d33ab9e8f8059db064"
    }
  },
  {
    "ts": null,
    "headline": "Padcev-Keytruda combo approved for NHS use in mUC",
    "summary": "The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.",
    "url": "https://finnhub.io/api/news?id=89825dcac1b28db6e5a3199e7098e65c6ea1b5887988ff259bd9db4a253592ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755795863,
      "headline": "Padcev-Keytruda combo approved for NHS use in mUC",
      "id": 136471625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.",
      "url": "https://finnhub.io/api/news?id=89825dcac1b28db6e5a3199e7098e65c6ea1b5887988ff259bd9db4a253592ae"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=da8218da74029930319739ebbb0c30d124d26fcc06efb5975b893e1b02bdf4e5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755794160,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 136490549,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=da8218da74029930319739ebbb0c30d124d26fcc06efb5975b893e1b02bdf4e5"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
    "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755793800,
      "headline": "[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136467561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Biologics and Biosimilars Market size & share revenue was valued at approximately USD 478.83 Billion in 2024 and is expected to reach USD 527.36 Billion in 2025 and is expected to reach around USD 1,320.19 Billion by 2034, at a CAGR of 10.42% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen Inc., P",
      "url": "https://finnhub.io/api/news?id=9aaef2be70e1f2d712f1b47c8b1dce64987548f13e4fff641e2d6a7b53569d78"
    }
  },
  {
    "ts": null,
    "headline": "US-EU trade deal impacts on pharma industry more 'manageable' than expected",
    "summary": "A trade deal framework between the US and EU is causing less pain than anticipated for pharma.",
    "url": "https://finnhub.io/api/news?id=b2d3563e71b4a5f4a3af88b9e03d3e16afa04b85b3be2d415daa356edef90535",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755790362,
      "headline": "US-EU trade deal impacts on pharma industry more 'manageable' than expected",
      "id": 136467562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A trade deal framework between the US and EU is causing less pain than anticipated for pharma.",
      "url": "https://finnhub.io/api/news?id=b2d3563e71b4a5f4a3af88b9e03d3e16afa04b85b3be2d415daa356edef90535"
    }
  },
  {
    "ts": null,
    "headline": "Low Volatility Calls For This Breakout Trade On Pfizer Stock",
    "summary": "Pfizer stock currently trades at very low volatility. That could mean it’s ripe for a breakout trade, like a long strangle.",
    "url": "https://finnhub.io/api/news?id=18097b6a8916290eb4ec8301b37628cccef34162d50a8a594abcb98ccc38103f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755789345,
      "headline": "Low Volatility Calls For This Breakout Trade On Pfizer Stock",
      "id": 136467845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer stock currently trades at very low volatility. That could mean it’s ripe for a breakout trade, like a long strangle.",
      "url": "https://finnhub.io/api/news?id=18097b6a8916290eb4ec8301b37628cccef34162d50a8a594abcb98ccc38103f"
    }
  },
  {
    "ts": null,
    "headline": "Has Pfizer Inc.'s (NYSE:PFE) Impressive Stock Performance Got Anything to Do With Its Fundamentals?",
    "summary": "Pfizer's (NYSE:PFE) stock is up by a considerable 10% over the past three months. We wonder if and what role the...",
    "url": "https://finnhub.io/api/news?id=3917d8c809fe11b26faf7e4478690f9279db7b64862ceab671d0b3c00807fa6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755781213,
      "headline": "Has Pfizer Inc.'s (NYSE:PFE) Impressive Stock Performance Got Anything to Do With Its Fundamentals?",
      "id": 136467846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's (NYSE:PFE) stock is up by a considerable 10% over the past three months. We wonder if and what role the...",
      "url": "https://finnhub.io/api/news?id=3917d8c809fe11b26faf7e4478690f9279db7b64862ceab671d0b3c00807fa6c"
    }
  },
  {
    "ts": null,
    "headline": "Leaders Come Together to Advance the Industry at Veeva Summit",
    "summary": "Veeva Systems (NYSE: VEEV) today announced highlights of its upcoming Veeva R&D and Quality Summit, where leaders across life sciences and Veeva exchange impactful ideas and innovations. BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer are among the leaders coming together September 3-4 in Boston to share how they are advancing clinical, regulatory, safety, and quality.",
    "url": "https://finnhub.io/api/news?id=26a468193de7bd021b5caf35fcf05380c75519b7984d369a471a769d51208da7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755774180,
      "headline": "Leaders Come Together to Advance the Industry at Veeva Summit",
      "id": 136452617,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Veeva Systems (NYSE: VEEV) today announced highlights of its upcoming Veeva R&D and Quality Summit, where leaders across life sciences and Veeva exchange impactful ideas and innovations. BeOne Medicines, Intercept Pharmaceuticals, Merck, and Pfizer are among the leaders coming together September 3-4 in Boston to share how they are advancing clinical, regulatory, safety, and quality.",
      "url": "https://finnhub.io/api/news?id=26a468193de7bd021b5caf35fcf05380c75519b7984d369a471a769d51208da7"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Shares Are Cheap, But They Could Get Even Cheaper Next Year",
    "summary": "I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat.",
    "url": "https://finnhub.io/api/news?id=14acf641000636cd127d58df1a7fe9d6a3ddac89f58d68e9d72e003fb9781e10",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755770123,
      "headline": "Pfizer: Shares Are Cheap, But They Could Get Even Cheaper Next Year",
      "id": 136455923,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172492554/image_2172492554.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat.",
      "url": "https://finnhub.io/api/news?id=14acf641000636cd127d58df1a7fe9d6a3ddac89f58d68e9d72e003fb9781e10"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Stagnation Is An Investment Opportunity",
    "summary": "Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Find out why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=97f1df5f20ae580b6073a385b457d798914fe25c554a3411bb137c3ed9e43f66",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755748053,
      "headline": "Pfizer: Stagnation Is An Investment Opportunity",
      "id": 136451206,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149808923/image_2149808923.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Find out why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=97f1df5f20ae580b6073a385b457d798914fe25c554a3411bb137c3ed9e43f66"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: sued in Europe by Enanta for patent infringement",
    "summary": "US biotech company Enanta Pharmaceuticals announced on Wednesday that it had filed a complaint with the EU's Unified Patent Court against pharmaceutical giant Pfizer, accusing it of infringing a...",
    "url": "https://finnhub.io/api/news?id=5f0d4e3653ea97c55f583809b85a56a70ab1e7f461c42e19cffad599586e62e7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755746056,
      "headline": "Pfizer: sued in Europe by Enanta for patent infringement",
      "id": 136450762,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "US biotech company Enanta Pharmaceuticals announced on Wednesday that it had filed a complaint with the EU's Unified Patent Court against pharmaceutical giant Pfizer, accusing it of infringing a...",
      "url": "https://finnhub.io/api/news?id=5f0d4e3653ea97c55f583809b85a56a70ab1e7f461c42e19cffad599586e62e7"
    }
  },
  {
    "ts": null,
    "headline": "How Much Would It Take To Earn $100 A Month From Pfizer Stock",
    "summary": "Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q3 2025 earnings on Oct. 28. Wall Street analysts expect the company to post EPS of $0.86, down from $1.06 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $17.11 billion, down from $17.70 billion a year earlier. The 52-week range of Pfizer stock price was $20.92 to $30.43. Pfizer's dividend yield is 6.86%.",
    "url": "https://finnhub.io/api/news?id=1191e8eb9b5badc8d79d4254b2bd3e96a213da06403c9dff7f4a5548b03e47f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755741682,
      "headline": "How Much Would It Take To Earn $100 A Month From Pfizer Stock",
      "id": 136450401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) discovers, develops, markets, and sells biopharmaceutical products in the U.S. and internationally. It will report its Q3 2025 earnings on Oct. 28. Wall Street analysts expect the company to post EPS of $0.86, down from $1.06 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $17.11 billion, down from $17.70 billion a year earlier. The 52-week range of Pfizer stock price was $20.92 to $30.43. Pfizer's dividend yield is 6.86%.",
      "url": "https://finnhub.io/api/news?id=1191e8eb9b5badc8d79d4254b2bd3e96a213da06403c9dff7f4a5548b03e47f1"
    }
  }
]